

# **An Introduction of Beijing Tide Pharmaceutical Co., Ltd.**

## **General Introduction**

Established in 1995, Beijing TIDE Pharmaceutical Co., Ltd. is primarily a new and high technology enterprise developing and manufacturing medicine products. Located at the central position of Beijing Yizhuang State-level Economic and Technological Development Area, it occupies a land area of 32,000m<sup>2</sup>, and the building area of Phase 1 construction is 14,600m<sup>2</sup>. All fully automatic production lines in the GMP workshop are the best ones in the world, with the major equipment of them are completely imported from abroad. It is capable to produce the injections, oral solid preparations and other preparations, where the yearly capacity of injections has reached 12 million tubes, and oral solid preparations 500 million tablets (grains).

Beijing TIDE Pharmaceutical Co., Ltd. launched in 1998 its first lipid micro-sphere series targeting product 凯时® injection, and its second lipid micro-sphere series targeting product - 凯纷® injection in 2004, both of them have gained great economic and social benefits; by which we are not only encouraged to continue our research and development in the lipid microsphere series targeting products, but also enhance our cooperation with the drug research institutes and pharmaceutical enterprises at home and abroad, to develop and manufacture other new and high technology products to benefit the people.

Presently, Beijing TIDE Pharmaceutical Co., Ltd. has more than 400 employees, including more than 20 R&D personnel and some 300 marketing and academic promotion personnel; it has set up 31 offices all over China, and 80% of the market and technology extension personnel are at least graduates of medicine specialty. With the continuous growth, Beijing TIDE Pharmaceutical Co., Ltd. shall admit more personnel of outstanding ability to join it and make greater contributions to the Chinese medicine undertakings.

## **The Main Products**

KAISHI is alprostadil Lipo carrier targeting injection and the first and unique Lipo carrier targeting drug recognized by SFDA in China. KAISHI is made in the unique technique and made into O/W type of Lipo carrier targeting preparation that alprostadil is enveloped in the Lipo of 200nm diameter through the course of high pressure, isotope and emulsification. Lipo, as the carrier of drugs, can bring alprostadil to the wound pathological vessel and inflammation position in high performance and target, realize the targeting treatment of the drugs. At the same time, because of the Lipo of envelopment, the inactivation of alprostadil in the lung is avoided, the dosage of the drug is greatly reduced and the side effect of the drug is obviously lowered. Alprostadil, which is the main component of KAISHI, is a kind of physiologically active substance in vivo, whose activity is strong, and has pharmacological action of expanding vessels and restraining platelet aggregation obviously. The clinical application of KAISHI is wide and mainly used in peripheral pathological changes, microcirculation disturbance of the heart and the brain, organ transplantation and organ protection and so on.

KAIFEN is flurbiprofen injection and the unique non-steroid targeting analgesic by intravenous injection sold in China, which has the four characters of targeting analgesia, balancing analgesia, forestalling analgesia and comfort analgesia.

Targeting analgesia: The drugs target the operative incision and tumor site, get together in high concentration locally and restrain the synthesis of the pain producing substance----PG.

Balancing analgesia: KAIFEN can be applied together with morphine, which enhances analgesia in geometric progression.

Forestalling analgesia: KAIFEN can step up the pain threshold, reduce the algesia conduction of the nerve terminal and lessen the sensitization of the center.

Comfort analgesia: The safety factor of KAIFEN is 20 times of traditional non-steroid targeting analgesic, when it is applied together with morphine, the dosage of morphine can be reduced 50% and the severe side effect caused by morphine, such as respiratory depression can be decreased.

### **The Projects seeking for cooperation**

- 1) Sole agency of sales in China for prescribed medicine
- 2) Technology transfer and license of manufacturing and sales of prescribed medicine
- 3) Advanced preparation of prescribed medicine such as micro-sphere delivery